yuval_shap Profile Banner
Yuval Shapir Itai Profile
Yuval Shapir Itai

@yuval_shap

Followers
151
Following
659
Media
16
Statuses
98

Post-doc at @dahanlab, WIS. Antibody mediated immunity and immunotherapy.

Weizmann Institute of Science
Joined October 2020
Don't wanna be here? Send us removal request.
@yuval_shap
Yuval Shapir Itai
2 years
I'm very excited to share my PhD work and first first-author paper. Meet BiCE, our bispecific DC-T cell engager designed to potentiate aPD-1 immunotherapy, published today in @CellCellPress. Big thanks to my mentor @DahanLab and our collaborators @orenbarboy and @IdoAmitLabโœด๏ธ
@DahanLab
Rony Dahan
2 years
Together with @IdoAmitLab weโ€™re very excited to introduce BiCE (Bispecific DC-T Cell Engager)- a new platform to engineer immune cell communication for #cancer #immunotherapy. Led by the amazing @yuval_shap @orenbarboy, now out @CellCellPress: https://t.co/COVWAN7Tbf (1/11)
4
10
61
@yuval_shap
Yuval Shapir Itai
8 months
Check out this beautiful story championed by @FadiSheban of the @IdoAmitLab, published today in @Cancer_Cell ๐Ÿš€ @FadiSheban, thanks for bringing me in to be a small part of the team, the best scientific discussions and the coffee โ˜•๏ธ
@IdoAmitLab
IdoAmitLab
8 months
We are excited to share our new study @Cancer_Cell identifying Zeb2 as a master genetic switch controlling the tumor-associated macrophage (TAM) program. Led by @FadiSheban, @TgSanPhan, @CuriousKX & @FlorianIngelfi1. (1/20) https://t.co/ZpPXUjbwRF
2
1
16
@yuval_shap
Yuval Shapir Itai
10 months
0
0
1
@yuval_shap
Yuval Shapir Itai
10 months
Excited to see our BiCE highlighted as an emerging strategy to enhance cDC1-mediated cross-priming ๐Ÿคฉ @DahanLab @IdoAmitLab
@NatureRevCancer
Nature Reviews Cancer
10 months
NEW content online! Cross-priming in cancer immunology and immunotherapy https://t.co/j3bqHUJ8ma
1
24
18
@yuval_shap
Yuval Shapir Itai
1 year
Had a great time presenting our work and hearing about exciting new science at the 3rd @ImmunoSens - IFReC International School on Advanced Immunology in Japan. Thanks for the amazing opportunity ๐Ÿ™๐Ÿผ @DahanLab
0
1
14
@yuval_shap
Yuval Shapir Itai
1 year
Link to our BiCE paper published in @CellCellPress https://t.co/8cqOCX1qr5
0
0
3
@yuval_shap
Yuval Shapir Itai
1 year
Link to our publication: https://t.co/GdppRwAcCj
1
0
2
@yuval_shap
Yuval Shapir Itai
1 year
If youโ€™re interested in our protocols for cell doublet quantification and imagestream analysis from our #BiCE paper, or if you have a bispecific engager of your own that youโ€™d like to test, check out our new protocol from @DahanLab with @PoratZiv published in @STARProtocols ๐Ÿซง
2
3
15
@WeizmannScience
Weizmann Institute
1 year
Congratulations to Yuval Shapir of the Systems Immunology Department (from the group of Dr. Rony Dahan) for being awarded the EPHAR-EACPT Young Investigator Awards @yuval_shap
0
2
25
@yuval_shap
Yuval Shapir Itai
1 year
Excited to share that Iโ€™ve been awarded the EACPT-EPHAR Young Investigator Award in Translational Pharmacology, and the opportunity to present our work here in Rotterdam. Thank you to @EACPT, @DahanLab and our collaborators ๐Ÿ™Œ๐Ÿผ
@DahanLab
Rony Dahan
1 year
Outstanding award presentation by @yuval_shap while receiving the EPHAR-EACPT Young Investigator Award in Translational Pharmacology. Congrats Yuval, we are very proud of you ๐Ÿ‘๐Ÿป ๐Ÿ† @EACPT @Sys_Immunology @WeizmannScience
2
1
12
@yuval_shap
Yuval Shapir Itai
2 years
I am honored to receive the 2024 Rappaport Prize in Biomedical Sciences for the development of new cancer immunotherapies. A big thank you to my mentor and PI, @DahanLab, my amazing labmates and collaborators, @WeizmannScience , and the @Sys_Immunology department ๐Ÿ™
@WeizmannScience
Weizmann Institute
2 years
Congratulations to @yuval_shap (from the group of Dr. Rony Dahan) upon being awarded the 2024 Rappaport Prize for an outstanding doctoral student for excellence in the field of Biomedical Research
1
0
20
@yuval_shap
Yuval Shapir Itai
2 years
Congrats @orenbarboy, Akhiad and teams! Happy to see this out, and always happy to collaborate โœจ
@IdoAmitLab
IdoAmitLab
2 years
We are proud to share our latest work, in collaboration with Amos Tanay lab, presenting a framework for in vivo tracking of CD8+ T cells' response to immunotherapy over time & at single-cell resolution, led by @orenbarboy and Akhiad Bercovich. https://t.co/Fmt4GoDEok. (1/19)
1
0
5
@yuval_shap
Yuval Shapir Itai
2 years
Honored to receive the 2024 Rappaport Prize in Biomedical Sciences for the development of new cancer immunotherapies. A big thank you to my mentor and PI Rony @DahanLab , @Sys_Immunology @WeizmannScience for making my science dreams a reality.
@Sys_Immunology
Systems_Immunology_WIS
2 years
2/3 โ€ฆResearch, for her groundbreaking discoveries in proteostasis and protein degradation regulation and their important ramifications on human disease. Huge Kudos Yifat! And to make us even prouder, Yuval Shapir @yuval_shap of @DahanLab has been awarded the 2024 Rappaportโ€ฆ
6
3
48
@CD_AACR
Cancer Discovery
2 years
Read this week's Cancer Discovery #ResearchWatch: A Bispecific Dendritic #Tcell Engager Induces Potent Antitumor Immunity, a summary of the paper by @yuval_shap, @orenbarboy, @IdoAmitLab, @DahanLab et al. https://t.co/msfTt2K5Fl @WeizmannScience
0
4
11
@yuval_shap
Yuval Shapir Itai
2 years
Thank you for highlighting our work! โ˜•๏ธ @NatRevDrugDisc @DahanLab @IdoAmitLab https://t.co/MaGxFU8AKh
0
2
8
@LaskerFDN
Lasker Foundation
2 years
A new cancer #immunotherapy approach uses a bispecific antibody to bring #Tcells and #dendriticcells together. Antibody-treated mice show enhanced immune reprogramming, both in tumors and in tumor-draining lymph nodes. @DahanLab @IdoAmitLab https://t.co/2CWWQvXLJv
0
5
26
@CellCellPress
Cell
2 years
In the latest issue! Bispecific dendritic-T cell engager potentiates anti-tumor immunity
0
33
106
@DrawImpacts
DrawImpacts
2 years
๐Ÿ”ŒWe had a blast working with the @DahanLab @yuval_shap to illustrate their latest paper on BiCE (Bispecific DC-T Cell Engager), a new bispecific DC-T cell engager designed to potentiate aPD-1 immunotherapy! ๐Ÿ’กLearn more about their amazing work:
@DahanLab
Rony Dahan
2 years
Together with @IdoAmitLab weโ€™re very excited to introduce BiCE (Bispecific DC-T Cell Engager)- a new platform to engineer immune cell communication for #cancer #immunotherapy. Led by the amazing @yuval_shap @orenbarboy, now out @CellCellPress: https://t.co/COVWAN7Tbf (1/11)
1
1
14
@yuval_shap
Yuval Shapir Itai
2 years
In the beautiful artwork by @DrawImpacts, T-DC interactions potentiate the immune circuts necessary to illuminate the tumor microenvironment. @DahanLab @IdoAmitLab
1
1
1
@Haaretz
Haaretz ื”ืืจืฅ
2 years
ื‘ืขื–ืจืช ืฉื™ืœื•ื‘ ืชืื™ื ื—ื™ืกื•ื ื™ื™ื, ื‘ืžื›ื•ืŸ ื•ื™ืฆืžืŸ ืžืฆื™ื’ื™ื ื’ื™ืฉื” ื—ื“ืฉื” ืœื˜ื™ืคื•ืœ ื‘ืกืจื˜ืŸ
haaretz.co.il
ื”ืืจืฅ
0
3
9